Next Article in Journal
Simple Sequence Repeat Polymorphisms (SSRPs) for Evaluation of Molecular Diversity and Germplasm Classification of Minor Crops
Next Article in Special Issue
Effects of α-Melanocortin Enantiomers on Acetaminophen-Induced Hepatotoxicity in CBA Mice
Previous Article in Journal
Antioxidant Effects of Some Drugs on Immobilization Stress Combined with Cold Restraint Stress
Previous Article in Special Issue
Soft Alkyl Ether Prodrugs of a Model Phenolic Drug: The Effect of Incorporation of Ethyleneoxy Groups on Transdermal Delivery
Open AccessReview

Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy

1
Angiogenesis and Cancer Research Group, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand
2
Auckland Cancer Society Research Centre, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
*
Author to whom correspondence should be addressed.
Molecules 2009, 14(11), 4517-4545; https://doi.org/10.3390/molecules14114517
Received: 10 October 2009 / Revised: 3 November 2009 / Accepted: 5 November 2009 / Published: 10 November 2009
(This article belongs to the Special Issue Prodrugs)
Gene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert nontoxic prodrugs to cytotoxic drugs. A zone of cell kill around gene-modified cells due to transfer of toxic metabolites, known as the bystander effect, leads to tumour regression. Here we discuss the implications of either striving for a strong bystander effect to overcome poor gene transfer, or avoiding the bystander effect to reduce potential systemic effects, with the aid of three successful GDEPT systems. This review concentrates on bystander effects and drug development with regard to these enzyme prodrug combinations, namely herpes simplex virus thymidine kinase (HSV-TK) with ganciclovir (GCV), cytosine deaminase (CD) from bacteria or yeast with 5-fluorocytodine (5-FC), and bacterial nitroreductase (NfsB) with 5-(azaridin-1-yl)-2,4-dinitrobenzamide (CB1954), and their respective derivatives. View Full-Text
Keywords: nitroreductase; thymidine kinase; cytosine deaminase; alkylating agents; chemotherapy nitroreductase; thymidine kinase; cytosine deaminase; alkylating agents; chemotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Dachs, G.U.; Hunt, M.A.; Syddall, S.; Singleton, D.C.; Patterson, A.V. Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy. Molecules 2009, 14, 4517-4545.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop